CVS — CVS Health Corp. stock price, charts and financials

QT63CVS Health Corp.

CVS Health Corp. (NYSE: CVS) is a Healthcare company in the Medical - Healthcare Plans industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
94.75
-0.95-0.99%
OverviewShort InterestFilings
CVSQT63CVS Health Corp.·NYSE
94.75-0.99%
News
Down 1.0% — CVS Health: I Wanted A Beat And Raise, I Got It, And I'm Still At 'Hold' (seekingalpha.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ELV+0.78%$397.29CI-1.19%$279.13HUM+0.11%$385.41UNH+0.62%$409.60CNC+0.81%$66.31MOH+0.97%$198.35OSCR+1.29%$28.26ALHC-4.07%$13.79
Snapshot
IndexS&P 500P/E24.99EPS (ttm)3.83Insider Own1.36%Shs Outstand1.28BPerf Week-8.36%
Market Cap122.11BForward P/E11.32EPS next Y8.46Insider Trans-22.04%Shs Float1.27BPerf Month-6.92%
Enterprise Value187.08BPEG3.91EPS next Q-Inst Own89.13%Short Float1.53%Perf Quarter9.55%
Income4.91BP/S0.29EPS this Y237.07%Inst Trans-Short Ratio2.35Perf Half Y25.38%
Sales415.10BP/B1.53EPS next Y10.52%ROA1.93%Short Interest19.52MPerf YTD20.59%
Book/sh-P/C6.42EPS next 5Y12.36%ROE6.43%52W High109.58 -13.53%Perf Year50.66%
Cash/sh-P/FCF8.06EPS past 3/5Y-24.73% -23.94%ROIC4.09%52W Low61.93 53.00%Perf 3Y25.25%
Dividend Est.2.66 (2.81%)EV/EBITDA15.23Sales past 3/5Y7.63% 8.39%Gross Margin14.15%Volatility3.30% 2.59%Perf 5Y16.20%
Dividend TTM2.66 (2.81%)EV/Sales0.45EPS Y/Y TTM-37.98%Oper. Margin2.00%ATR (14)3.07Perf 10Y2.47%
Dividend Ex-DateJul 23, 2026Quick Ratio0.66Sales Y/Y TTM9.41%Profit Margin1.18%RSI (14)31.68Recom2.10
Dividend Gr. 3/5Y6.53% 5.87%Current Ratio0.87EPS Q/Q14.22%SMA20-9.10%Beta0.56Target Price110.21
Payout86.89%Debt/Eq0.96Sales Q/Q6.17%SMA50-6.06%Rel Volume1.44Prev Close95.70
Employees259,500LT Debt/Eq1.16EarningsNov 04SMA20012.53%Avg Volume8.46MPrice94.75
IPO DateFeb 21, 1973Option/ShortYes / YesEPS/Sales Surpr.17.70% 5.72%Net Debt/EBITDA5.29Volume12,155,305Change-0.99%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-06-26ReiteratedRobert W. Baird$94 → $107
Aug-06-26ReiteratedUBSBuy$122 → $126
Aug-06-26ReiteratedBarclaysOverweight$106 → $108
Jul-24-26ReiteratedUBSBuy$97 → $122
Jul-14-26ReiteratedTruist SecuritiesBuy$108 → $118
Jul-13-26ReiteratedWells FargoOverweight$103 → $123
Jul-09-26ReiteratedRBC CapitalOutperform$107 → $113
Jul-07-26ReiteratedCantor FitzgeraldOverweight$115 → $110
Jul-06-26ReiteratedHSBC$85 → $103
Jun-08-26ReiteratedMizuhoOutperform$110 → $115
Latest News
Today
Today09:42AM
CVS Health: I Wanted A Beat And Raise, I Got It, And I'm Still At 'Hold'seekingalpha.com
Aug-07-26
Aug-07-2603:43PM
Broad Market Momentum & Defensive Pivots: This Week's Top ETF Flowsetftrends.com
Aug-06-26
Aug-06-2611:05AM
CVS Q2 Earnings Call Pairs Aetna Recovery With 2027 PBM Riskszacks.com
10:05AM
Medicare Made Weight-Loss Drugs $50 A Month—Now Amazon, CVS And Walmart Race To Fill Prescriptionsforbes.com
08:06AM
CVS Health Q2 Earnings Call Highlightsmarketbeat.com
Aug-05-26
Aug-05-2608:12PM
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectationszacks.com
02:04PM
CVS Health Corp (CVS) (Q2 2026) Earnings Call Highlights: Strong Earnings Beat and Raised Guidance Signal Accelerating Turnaroundgurufocus.com
01:36PM
CVS Stock Drops 5.8% as 2027 Outlook Disappointsgurufocus.com
12:00PM
CVS Health Corporation (CVS) Q2 2026 Earnings Call Transcriptseekingalpha.com
11:36AM
ADP Cools to +44K, Earnings Show Beats from DIS, LLY & Morezacks.com
11:20AM
CVS Health Q2 Earnings and Revenues Top Estimates, Stock Climbszacks.com
10:55AM
CVS Health tops second-quarter estimates, raises full-year profit outlookproactiveinvestors.com
10:41AM
Here's Why CVS Health (CVS) is a Strong Value Stockzacks.com
10:31AM
CVS Health (CVS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimateszacks.com
08:46AM
CVS Health (CVS) Q2 Earnings and Revenues Beat Estimateszacks.com
Company

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Ownership
Total institutional ownership89.13%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue415,086402,067372,809——————
Cost of Goods Sold Incl. D&A356,340346,705321,408——————
Gross Profit58,74655,36251,401——————
Selling, General and Administrative Excl. Other0041,229——————
Research and Development
000——————
Other Operating Expense50,45844,9771,656——————
Operating Income8,28810,3858,516——————
Interest Expense3,1023,1192,958——————
Unusual Expense
—————————
Non-Operating Income (Expense)601-5,130590——————
Net Income Before Taxes5,7872,1366,148——————
Income Taxes9164081,562——————
Consolidated Net Income4,9061,7684,614——————
Net Income From Continuing Operations4,8711,7284,586——————
Net Income4,9061,7684,614——————
EPS (Recurring)3.831.403.66——————
EPS (Basic, Before Extraordinaries)3.831.403.66——————
EPS (Diluted)3.781.393.66——————
EBITDA12,2859,86113,683——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio25.0757.0912.27——————
Price To Sales Ratio0.290.250.15——————
Gross Margin14.1513.7713.79——————
Operating Margin2.002.582.28——————
Net Margin1.180.441.24——————
Shares Outstanding1,2761,2671,259——————
Market Capitalization120,901100,54956,517——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$118.38$101.53$84.67$67.82$50.97● Close Price0.00M86.43M172.87M259.30M345.74MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
ROBBINS LARRYDirectorMay 21 '26Sale75.69748,46256,652,6270May 21
ROBBINS LARRYDirectorMay 20 '26Sale93.821,018,00095,510,8225,195,261May 21
ROBBINS LARRYDirectorMay 19 '26Sale94.451,983,538187,341,3076,213,261May 21
Mandadi TilakEVP, Chief Exp & Tech OfficerMay 08 '26Sale89.5869,5516,230,37910,133May 11
Nelson Steven HEVP and President, AetnaJan 23 '25Buy53.70241,28924Jan 27
CAPOZZI HEIDI BEVP and Chief People OfficerOct 23 '24Buy56.85351,99085Oct 14
CAPOZZI HEIDI BEVP and Chief People OfficerOct 02 '24Buy62.241062250Oct 14
CAPOZZI HEIDI BEVP and Chief People OfficerSep 09 '24Buy56.47351,97640Oct 14
Finucane Anne A.DirectorAug 20 '25Sale71.027,500532,65022,156Aug 29
SANSONE GUY PDirectorJun 05 '25Buy63.701,570100,00912,007Jun 09
ROBBINS LARRYDirectorMay 06 '25Sale66.67150,00010,000,7108,196,799May 06
ROBBINS LARRYDirectorMay 05 '25Sale67.411,323,93289,249,9458,346,799May 06
ROBBINS LARRYDirectorMay 02 '25Sale67.862,276,068154,444,7589,670,731May 06
Shah Prem SEVP and Group PresidentMar 17 '25Option Exercise62.2184652,63043,190Mar 18
Clark James DavidSVP, Cont & Chief Acct OfficerMar 05 '25Option Exercise62.217,513467,38415,907Mar 07
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.